Brittany Beard
Family · Martinsburg, WVNPI 1619682408
Payments from drug & device makers
Across 107 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$418
- Novo Nordisk$409
- AstraZeneca$240
- Lilly USA, LLC$180
- Amgen$162
- Pfizer$139
- plus $449 from 11 others
What the payments were for
- Food & beverage$1,997100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $418 |
| Novo Nordisk | 24 | $409 |
| AstraZeneca | 14 | $240 |
| Lilly USA, LLC | 11 | $180 |
| Amgen | 9 | $162 |
| Pfizer | 8 | $139 |
| Merck | 5 | $122 |
| GSK | 4 | $77 |
| Bayer | 2 | $46 |
| Hologic Sales And Service, LLC | 1 | $35 |
| Gilead | 1 | $30 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Alkermes, Inc. | 1 | $26 |
| Viiv Healthcare Company | 1 | $26 |
| Biogen | 1 | $20 |
| Seqirus USA Inc | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
How this compares
$1,997 in reported general payments places this provider in the 80th percentile of 1,507 family providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 40 | $149,037 |
| MounjaroTirzepatide | 54 | $82,428 |
| OzempicSemaglutide | 75 | $81,476 |
| TrulicityDulaglutide | 39 | $56,424 |
| JardianceEmpagliflozin | 41 | $47,421 |
| FarxigaDapagliflozin Propanediol | 38 | $45,717 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $26,173 |
| EliquisApixaban | 22 | $18,783 |
| TradjentaLinagliptin | 17 | $13,380 |
| JanuviaSitagliptin Phosphate | 12 | $12,567 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $9,920 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $7,766 |
| Tiotropium Bromide | 15 | $7,630 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $7,261 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $6,996 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $30 | $149,03740 claims |
| Lilly USA, LLCMounjaro, Trulicity | $180 | $138,85293 claims |
| Novo NordiskOzempic | $409 | $81,47675 claims |
| AstraZenecaFarxiga, Symbicort | $240 | $53,48361 claims |
| PfizerEliquis | $139 | $18,78322 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $77 | $14,41225 claims |
| MerckJanuvia | $122 | $12,56712 claims |
| AbbVieSavella, Synthroid | $418 | $5,01925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,507 family providers in West Virginia.
Other family in Martinsburg
- Stephanie GladdenMartinsburg$7K
- Ashley ComerCharleston$213K
- Dana CruseParkersburg$109K
- Sarah KnightCharleston$99K
- Star RoeBarboursville$55K
- Angela SettleCharleston$51K
- Amber DuncanCross Lanes$44K
- Jennifer FieldsHuntington$32K
- Gina LatheyScott Depot$31K
- Jodi BillerScott Depot$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.